Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study
Franck Morschhauser(Hôpital Claude Huriez), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Jeremy S. Abramson(Massachusetts General Hospital), Isabelle Fleury(Hôpital Maisonneuve-Rosemont), Anna Maria Barbui(Ospedale Papa Giovanni XXIII), Hideki Goto(Hokkaido University Hospital), Alan P Skarbnik(Novant Health), Saurabh Dahiya(Stanford University), Jessica Papuga(Bristol-Myers Squibb (Switzerland)), Koji Izutsu(Tokyo National Hospital), Guillaume Cartron(Hôpital Saint Eloi), Ulrich Jäger(Medical University of Vienna), Rina Nishii(Bristol-Myers Squibb (United States)), Alejandro Martı́n(Instituto de Investigación Biomédica de Salamanca), Min Vedal(Bristol-Myers Squibb (United States)), Jinender Kumar(Bristol-Myers Squibb (United States)), Stephan Mielke(Karolinska University Hospital), Thalia A. Farazi(Bristol-Myers Squibb (United States)), Martin Dreyling(German Cancer Research Center), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Kirit M. Ardeshna(UCL Biomedical Research Centre), Peter Borchmann(University of Cologne), James Lymp(Mayo Clinic), Andreas Viardot(University Hospital Ulm), Brad S. Kahl(UW Health University Hospital), Juan Luis Reguera Ortega(Universidad de Sevilla), Hervé Ghesquières(Université Claude Bernard Lyon 1), Sven de Vos(University of California, Los Angeles), John Kuruvilla(Princess Margaret Cancer Centre), Omotayo Fasan(Bristol-Myers Squibb (United States)), Reem Karmali(Northwestern University), Ariel Avilion(Bristol-Myers Squibb (United States)), Manali Kamdar(University of Colorado Cancer Center)
Cited by 127
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k